Calciphylaxis: a systematic review of existing and emerging therapies.

Chetan Vedvyas, Laura S Winterfield, Ruth Ann Vleugels

Journal: Journal of the American Academy of Dermatology 2013;67(6):e253-60

PMID: 21821309

Full Text on Elsevier Science View on PubMed

Abstract

Calciphylaxis, also known as calcific uremic arteriolopathy, is a cutaneous ischemic small vessel vasculopathy seen in 1 to 4% of patients with chronic kidney disease on hemodialysis. It is associated with extreme pain and a 60 to 80% mortality rate in the setting of few and frequently ineffective therapeutic options, although this may be changing based on reports of success with newer therapies.

Address: Harvard Medical School, Boston, Massachusetts 02115, USA. [email protected]

DOI: 10.1016/j.jaad.2011.06.009

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Antioxidants, Calciphylaxis, Cinacalcet, Diphosphonates, Humans, Naphthalenes, Parathyroidectomy, Skin Diseases, Vascular, Thiosulfates